Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions
Authors:
- 14 July 2009
- journal article
- review article
- Published by Springer Nature in International Journal of Obesity
- Vol. 33 (9) , 947-955
Abstract
Rimonabant and taranabant are two extensively studied cannabinoid-1 receptor (CB1R) inverse agonists. Their effects on in vivo peripheral tissue metabolism are generally well replicated. The central nervous system site of action of taranabant or rimonabant is firmly established based on brain receptor occupancy studies. At the whole-body level, the mechanism of action of CB1R inverse agonists includes a reduction in food intake and an increase in energy expenditure. At the tissue level, fat mass reduction, liver lipid reduction and improved insulin sensitivity have been shown. These effects on tissue metabolism are readily explained by CB1R inverse agonist acting on brain CB1R and indirectly influencing the tissue metabolism through the autonomic nervous system. It has also been hypothesized that rimonabant acts directly on adipocytes, hepatocytes, pancreatic islets or skeletal muscle in addition to acting on brain CB1R, although strong support for the contribution of peripherally located CB1R to in vivo efficacy is still lacking. This review will carefully examine the published literature and provide a perspective on what new tools and studies are required to address the peripheral site of action hypothesis.Keywords
This publication has 70 references indexed in Scilit:
- Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in miceBioorganic & Medicinal Chemistry Letters, 2009
- Should peripheral CB1 cannabinoid receptors be selectively targeted for therapeutic gain?Trends in Pharmacological Sciences, 2009
- Peripheral, but Not Central, CB1 Antagonism Provides Food Intake–Independent Metabolic Benefits in Diet-Induced Obese RatsDiabetes, 2008
- Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in miceJournal of Clinical Investigation, 2008
- Endocannabinoid system in food intake and metabolic regulationCurrent Opinion in Lipidology, 2008
- [18F]MK-9470, a positron emission tomography (PET) tracer forin vivohuman PET brain imaging of the cannabinoid-1 receptorProceedings of the National Academy of Sciences, 2007
- Antiobesity Efficacy of a Novel Cannabinoid-1 Receptor Inverse Agonist, N-[(1 S,2 S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), in RodentsThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Effects of cannabinoid receptors on skeletal muscle oxidative pathwaysMolecular and Cellular Endocrinology, 2007
- Inverse agonism and neutral antagonism at cannabinoid CB1 receptorsLife Sciences, 2005
- Biochemical and pharmacological characterisatioN OF SR141716A, the first potent and selective brain cannabinoid receptor antagonistLife Sciences, 1995